Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
AstraZeneca
Express Scripts
Harvard Business School
Moodys

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RELENZA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Relenza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00784784 Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed GlaxoSmithKline Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00784784 Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed Mount Sinai Hospital, Canada Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00867139 TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Completed Fred Hutchinson Cancer Research Center Phase 1/Phase 2 2009-03-01 The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
NCT00921726 Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults Completed Johns Hopkins Bloomberg School of Public Health Phase 1 2009-07-01 Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults.
NCT00921726 Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2009-07-01 Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults.
NCT00979667 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated Food and Health Bureau, Hong Kong Phase 3 2009-10-01 To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
NCT00979667 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated Hospital Authority Phase 3 2009-10-01 To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Relenza

Condition Name

Condition Name for Relenza
Intervention Trials
Influenza, Human 4
Influenza 4
Upper Respiratory Tract Infection 1
Sinusitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Relenza
Intervention Trials
Influenza, Human 7
Virus Diseases 1
Chronic Disease 1
Sinusitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Relenza

Trials by Country

Trials by Country for Relenza
Location Trials
United States 26
China 8
Canada 5
Australia 5
Germany 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Relenza
Location Trials
Connecticut 1
Nevada 1
Georgia 1
Idaho 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Relenza

Clinical Trial Phase

Clinical Trial Phase for Relenza
Clinical Trial Phase Trials
Phase 3 3
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Relenza
Clinical Trial Phase Trials
Completed 7
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Relenza

Sponsor Name

Sponsor Name for Relenza
Sponsor Trials
GlaxoSmithKline 5
Mount Sinai Hospital, Canada 1
Chinese University of Hong Kong 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Relenza
Sponsor Trials
Other 6
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.